AAHI NEWS

Innovations • Global Impact • In The News • Our People

AAHI's Innovative Spray Dried Vaccine Platform

AAHI scientists develop aerosolized dry powder vaccine formulations to increase stability, ease of use, and effectiveness of vaccines against respiratory infectious diseases. 

INNOVATIONS

The latest scientific breakthroughs at AAHI.

Make your products accessible to those who need them most. Collaborate with AAHI.

GLOBAL IMPACT

FEBRUARY 2024

Collaboration across communities.

Explore AAHI's different areas of impact.

Washington D.C.

AAHI attends and presents at the world's leading vaccine event of the year

The team is looking forward to connecting with our partners and the international vaccine ecosystem in Washington D.C. April 1-4. Stop by booth 549 to say hello and learn more about AAHI's innovative approach to developing vaccine platform technologies to ensure practical accessibility worldwide.

Don't miss our panel, Vaccine Innovation: The Path to Global Health Resilience Thursday morning at 10:10am ET to discuss a proposal for addressing the critical need to establish consistent and reliable vaccine development to support readiness to meet the next infectious disease threat. 

The panel discussion will be streamed live for those of you who aren't able to make it to D.C.

Help us make impossible vaccines possible.

IN THE NEWS

By Gabrielle Masson

Fierce Biotech

Moderna's RNA respiratory syncytial virus (RSV) vaccine, MRNA-1345, showed a ~21% decline in efficacy (84% to 63%) in preventing RSV-associated respiratory tract disease from three to nine months following immunization. While there are important differences in study populations and methodologies, the findings appear to indicate a potentially faster efficacy rate decline than GSK's adjuvant-containing RSV vaccine Arexvy, which saw only ~6% decline (83% to 77%) from 7 to 14 months following immunization. These results may reveal differences in how each vaccine technology stimulates the immune system to provide protection against dsiease, and provoke scientists to consider more strategic combinations of the technologies in the face of public health emergencies. 

"One of the most important qualities of ajduvants is that they can prolong the immune response induced by vaccines. We continue to explore the potential of adjuvants to enhance and prolong immune responses to protein vaccine candidates as well as RNA vaccine candidates, including "heterologous" prime-boost regimens that combine adjuvanted protein and RNA vaccine approaches to provide rapid and long lasting protection against new infectious threats." - Christopher Fox, Senior Vice President, Formulations

OUR PEOPLE

Collaboration across communities.

Explore our different areas of impact.

Join the AAHI Community

On the morning of Thursday, April 4th, AAHI will be joined by public and private collaborators to discuss a proposal for addressing the critical need to establish consistent and reliable vaccine development to support readiness to meet the next infectious disease threat.

Openings and Opportunities

In-House Counsel

Legal/Compliance

The in-house counsel will be responsible for providing legal support for day-to-day operations and special matters, including legal research, drafting legal documents, and supporting the legal department and general counsel.

Legal Counsel (Government Contracting)

Legal/Compliance

The legal counsel will be responsible for providing legal counsel relating to AAHI's robust and growing portfolio of federal grants and contracts providing legal advice, drafting and finalizing agreements, and advising on contract performance and compliance. 

Learn more about our formulation technology

We partner with biotech leaders to develop vaccines and more.

Synthetic TLR4 ligand in squalene nanoemulsion

Synthetic TLR4 ligand in QS- 21 containing liposome

Synthetic TLR4 ligand in aqueous formulation

Dual agonist containing both TLR4 and TLR7/8 ligands

2nd-Gen synthetic TLR4 ligand
in squalene nanoemulsion

2nd-Gen synthetic TLR4 ligand
in QS-21 containing liposome

2nd-Gen synthetic TLR4 ligand
in aqueous formulation

Alum nanoparticle formulation, customized particle size

Synthetic TLR7/8 ligand in
squalene nanoemulsion

Synthetic TLR7/8 ligand
adsorbed to aluminum

Synthetic TLR7/8 ligand in
aqueous formulation

Nanostructured lipid carrier

See how our formulations are being used.